XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.2
Financial Royalty Assets, net - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2017
Nov. 30, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Jan. 31, 2025
Dec. 31, 2024
Aug. 31, 2024
Jul. 15, 2024
Mar. 31, 2024
Oct. 31, 2023
Finite-Lived Intangible Assets                        
Impairment loss of financial royalty assets     $ 0   $ 0 $ 26,491,000            
Gross carrying value     206,620,000   206,620,000     $ 198,587,000        
Ovid Therapeutics                        
Finite-Lived Intangible Assets                        
Impairment loss of financial royalty assets       $ 26,200,000                
Selexis                        
Finite-Lived Intangible Assets                        
Impairment loss of financial royalty assets           300,000            
Gross carrying value     186,000   186,000     205,000        
Ohtuvayre inventors                        
Finite-Lived Intangible Assets                        
Gross carrying value     16,637,000   16,637,000   $ 1,800,000 15,969,000 $ 13,600,000   $ 3,800,000  
Elutia (CorMatrix)                        
Finite-Lived Intangible Assets                        
Product royalty (as a percent) 5.00%                      
Gross carrying value     8,087,000   8,087,000     $ 9,418,000        
Proceeds from royalties received $ 10,000,000                      
Credit loss adjustment     $ (400,000) $ (1,500,000) $ (800,000) $ (4,600,000)            
Elutia (CorMatrix) | Maximum                        
Finite-Lived Intangible Assets                        
Additional royalties receivable under sales-based milestones $ 10,000,000                      
APEIRON                        
Finite-Lived Intangible Assets                        
Contract assets (financial royalty assets)                   $ 106,156,000    
Deferred tax liability                   18,109,000    
Tolerance Therapeutics (Tzield®)                        
Finite-Lived Intangible Assets                        
Cash payments for acquisition   $ 20,000,000                    
Product royalty (as a percent)   1.00%                    
Deferred tax liability   $ 5,500,000                    
Qarziba | APEIRON                        
Finite-Lived Intangible Assets                        
Contract assets (financial royalty assets)                   104,900,000    
InvIOs | APEIRON                        
Finite-Lived Intangible Assets                        
Contract assets (financial royalty assets)                   $ 1,300,000    
Soticlestat | Ovid Therapeutics                        
Finite-Lived Intangible Assets                        
Consideration paid for an interest in potential development milestone                       $ 30,000,000
Interest in sales revenue (as a percent)                       13.00%